An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

NCT02497469 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

771

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

DRUG: Vedolizumab
DRUG: Adalimumab placebo
DRUG: Adalimumab
DRUG: Vedolizumab placebo

Sponsor

Takeda